RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

BACKGROUND: RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit of second-line everolimus. Because of the high percentage of patients from Chin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lin, Alyasova, Anna, Ye, Dingwei, Ridolfi, Antonia, Dezzani, Luca, Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816475/
https://www.ncbi.nlm.nih.gov/pubmed/29454306
http://dx.doi.org/10.1186/s12885-018-4091-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816475/
https://www.ncbi.nlm.nih.gov/pubmed/29454306
http://dx.doi.org/10.1186/s12885-018-4091-5

Ejemplares similares